RxDoctor Payments Data

Jennifer Halfmann

Family · Lubbock, TXNPI 1609146448

Payments from drug & device makers

$1,283in general payments, 2019–2025

Across 67 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$379
  • Medtronic$202
  • Merck$160
  • Abbott$102
  • Pfizer$91
  • E.r. Squibb & Sons, L.L.C.$88
  • plus $260 from 8 others

What the payments were for

  • Food & beverage$1,283100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,283 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$5,970
Medicare patients
103
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban293$204,993
EntrestoSacubitril/Valsartan67$57,126
Repatha SureclickEvolocumab49$36,544
XareltoRivaroxaban34$34,224
VerquvoVericiguat19$15,409
BrilintaTicagrelor19$13,242
Praluent PenAlirocumab21$10,213
Rosuvastatin Calcium288$3,583
Carvedilol287$2,211
Flecainide Acetate57$1,781
Metoprolol Succinate165$1,540
Olmesartan Medoxomil89$1,344
Ranolazine ErRanolazine20$1,344
Atorvastatin Calcium126$1,308
ClopidogrelClopidogrel Bisulfate142$1,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$204,993293 claims
NovartisEntresto$379$57,12667 claims
Johnson & JohnsonXarelto$16$34,22434 claims
MerckVerquvo$160$15,40919 claims
AstraZenecaBrilinta$55$13,24219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →